A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism — SPARTAN

Priapism Clinical Trial

Official title:
A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism (SPARTAN)

Status Completed

Clinical Trial Summary

The goal of the study is to evaluate the efficacy and safety of crizanlizumab in SCD patients with priapism.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03938454
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 2
Start date	October 16, 2019
Completion date	November 29, 2023

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT00538564` - Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia	Phase 2
Withdrawn	`NCT01940718` - Androgen Regulation of Priapism in Sickle Cell Disease	N/A
Terminated	`NCT00940901` - Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia	Phase 2
Enrolling by invitation	`NCT04932902` - ManAgement of pRiapiSm and Its Impact on Outcomes
Completed	`NCT00300235` - Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence